Theravance Biopharma Stock Forecast

Stock Price Forecast

The 5 analysts that cover Theravance Biopharma stock have a consensus rating of "Buy" and an average price target of $18.4, which forecasts a 12.81% increase in the stock price over the next year. The lowest target is $15 and the highest is $24.

Price Target: $18.4 (+12.81%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$15	$18.4	$17	$24
Change	-8.03%	+12.81%	+4.23%	+47.15%

Analyst Ratings

The average analyst rating for Theravance Biopharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Nov '25	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26
Strong Buy	4	4	4	4	3	3
Buy	0	1	1	1	0	0
Hold	0	0	0	0	3	3
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	4	5	5	5	6	6

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Mayank Mamtani B. Riley Securities	B. Riley Securities	Hold Maintains $14 → $17	Hold	Maintains	$14 → $17	+4.23%	Apr 7, 2026
Marc Frahm TD Cowen	TD Cowen	Hold Maintains $13 → $15	Hold	Maintains	$13 → $15	-8.03%	Mar 23, 2026
Julian Harrison BTIG	BTIG	Strong Buy Reiterates $21	Strong Buy	Reiterates	$21	+28.76%	Mar 20, 2026
Trevor Allred Oppenheimer	Oppenheimer	Buy → Hold Downgrades n/a	Buy → Hold	Downgrades	n/a	n/a	Mar 5, 2026
Douglas Tsao HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $27 → $15	Strong Buy	Maintains	$27 → $15	-8.03%	Mar 4, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

116.56M

from 107.46M

8.46%

from 107.46M

Revenue Next Year

86.70M

from 116.56M

-25.62%

from 116.56M

EPS This Year

1.92

from 2.06

-6.91%

from 2.06

EPS Next Year

0.43

from 1.92

-77.34%

from 1.92

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	55.31M	51.35M	57.42M	64.38M	107.46M	116.56M	86.70M
Revenue Growth	-23.03%	-7.17%	11.84%	12.12%	66.92%	8.46%	-25.62%
EPS	-2.87	11.85	-1.00	-1.15	2.06	1.92	0.43
EPS Growth	-	-	-	-	-	-6.91%	-77.34%
Forward PE	-	-	-	-	-	8.51	37.54
No. Analysts	-	-	-	-	-	8	7

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	191.6M	94.1M
Avg	116.6M	86.7M
Low	75.9M	77.2M

Revenue Growth

Revenue Growth	2026	2027
High	78.3%	-19.3%
Avg	8.5%	-25.6%
Low	-29.4%	-33.7%

EPS Forecast

EPS	2026	2027
High	2.18	0.74
Avg	1.92	0.43
Low	1.48	0.15

EPS Growth

EPS Growth	2026	2027
High	6.0%	-61.6%
Avg	-6.9%	-77.3%
Low	-28.2%	-92.3%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.